# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 23 September 2004 (23.09.2004)

**PCT** 

## (10) International Publication Number WO 2004/080270 A3

(51) International Patent Classification<sup>7</sup>: 33/574, C12Q 1/44

G01N 33/68,

(21) International Application Number:

PCT/EP2004/002065

(22) International Filing Date: 27 February 2004 (27.02.2004)

(25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data: 03005386.2

13 March 2003 (13.03.2003) EF

- (71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GOLZ, Stefan [DE/DE]; Bückmannsmühle 46, 45326 Essen (DE). BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, 42799 Leichlingen (DE). GEERTS, Andreas [DE/DE]; Schuckertstr. 29, 42113 Wuppertal (DE).
- (74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 23 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH PHOSPHODIESTERASE 1B (PDE1B)

(57) Abstract: The invention provides a human PDE1B which is associated with the cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1B as well as pharmaceutical compositions comprising such compounds.



A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/68 G01N33/574 C12Q1/44

According to International Patent Classification (IPC) or to both national classification and IPC

Category °

C. DOCUMENTS CONSIDERED TO BE RELEVANT

 $\begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 C12Q G01N \\ \end{tabular}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data, MEDLINE, EMBASE

Citation of document, with indication, where appropriate, of the relevant passages

х	EP 1 085 092 A (PFIZER LTD ; PFI 21 March 2001 (2001-03-21) paragraph [0248] - paragraph [03 claims 9,11,12		1-25
P,X	WO 03/020702 A (CHILDRENS HOSP M CENTER; UNIV ROCKEFELLER (US)) 13 March 2003 (2003-03-13) page 16, line 24 - line 25; clai 5,19,27-33,53 page 44, last paragraph - page 4 paragraph 2	ms 5,	1-25
		-/	
	·		
İ		•	
X Furt	ther documents are listed in the continuation of box C.	Patent family members are listed	in annex.
° Special ca	ategories of cited documents :	"T" later document published after the into or priority date and not in conflict with	emational filing date
I consid	ent defining the general state of the art which is not dered to be of particular relevance	cited to understand the principle or th Invention	eory underlying the
"E" earlier document but published on or after the International filling date		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-	
later	than the priority date claimed	"&" document member of the same patent  Date of mailing of the international sea	
Date of the	actual completion of the international search		
	21 June 2004	2.5.	10. 2004

Authorized officer

Gunster, M

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Name and malling address of the ISA

Relevant to claim No.

### INTENATIONAL SEARCH REPORT

International Application No
PCT/EP2004/002065

	PC1/EP2004/002003
	Relevant to claim No.
Citation of document, with indication, where appropriate, of the relevant passages	Helevant to Gaim No.
KRUUSE CHRISTINA ET AL: "The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 420, no. 1, 18 May 2001 (2001-05-18), pages 55-65, XP002285171 ISSN: 0014-2999 page 64, last paragraph	19-21,24
US 6 372 777 B1 (MARTINS TIMOTHY J ET AL) 16 April 2002 (2002-04-16) column 10, line 8 - line 22 column 37, paragraph 4; claim 14	19-21,24
US 5 885 834 A (EPSTEIN PAUL M) 23 March 1999 (1999-03-23) cited in the application claim 1	19-21
JIANG XIN ET AL: "Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 20, 1996, pages 11236-11241, XP002285172 ISSN: 0027-8424 cited in the application page 11240, column 2, last paragraph	19-21
YU JOSEPHINE ET AL: "Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1" CELLULAR SIGNALLING, vol. 9, no. 7, 1997, pages 519-529, XP002285173 ISSN: 0898-6568 cited in the application figure 5	1-25
RYBALKIN SERGEI D ET AL: "Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype" JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 10, 15 November 1997 (1997-11-15), pages 2611-2621, XP002285174 ISSN: 0021-9738 page 2620, column 1, paragraph 4 - column 2, paragraph 2	1-25
	hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 420, no. 1, 18 May 2001 (2001-05-18), pages 55-65, XP002285171 ISSN: 0014-2999 page 64, last paragraph  US 6 372 777 B1 (MARTINS TIMOTHY J ET AL) 16 April 2002 (2002-04-16) column 10, line 8 - line 22 column 37, paragraph 4; claim 14  US 5 885 834 A (EPSTEIN PAUL M) 23 March 1999 (1999-03-23) cited in the application claim 1  JIANG XIN ET AL: "Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 20, 1996, pages 11236-11241, XP002285172 ISSN: 0027-8424 cited in the application page 11240, column 2, last paragraph  YU JOSEPHINE ET AL: "Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDEIB1" CELLULAR SIGNALLING, vol. 9, no. 7, 1997, pages 519-529, XP002285173 ISSN: 0898-6568 cited in the application figure 5  RYBALKIN SERGEI D ET AL: "Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDEIC) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype" JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 10, 15 November 1997 (1997-11-15), pages 2611-2621, XP002285174 ISSN: 0021-9738 page 2620, column 1, paragraph 4 - column 2, paragraph 2



	International Application No
ĺ	PCT/EP2004/002065

		PC1/EP2004/002005	
C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Category °	KOSTIC M M ET AL: "Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart" JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 29, no. 11, November 1997 (1997-11), pages 3135-3146, XP002278927 ISSN: 0022-2828 page 3144, column 1, line 9 - line 11	1-25	

International application No. PCT/EP2004/002065

### INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 26 because they relate to subject matter not required to be searched by this Authority, namely:  Rule 39.1(iv) PCT - Method for treatment of the human or animal body by
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  .
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
<ul> <li>4. X</li> <li>No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:</li> <li>1 - 26 (partially)</li> </ul>
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

# International Application No. PCT/ EP2004/ 002065 FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210 Continuation of Box II.1 Claims Nos.: 26 Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are cardiovascular diseases.

2. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are metabolic diseases.

3. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are gastrointestinal diseases.

4. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are liver diseases.

5. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are cancer disorders.

6. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are hematological diseases.

7. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are respiratory diseases.

8. claims: 1-26[partially]

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are neurological disorders.

9. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are urological diseases.

page 2 of 2

### INT NATIONAL SEARCH REPORT

Information on patent family members

# International Application No PCT/EP2004/002065

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1085092 A	21-03-2001	EP 1085092 A1 JP 2001149084 A	21-03-2001 05-06-2001
WO 03020702 A	13-03-2003	CA 2459161 A1 WO 03020702 A2 US 2003211040 A1	13-03-2003 13-03-2003 13-11-2003
US 6372777 B1	16-04-2002	US 2003013754 A1 AU 1087101 A CA 2395543 A1 CN 1434799 T EP 1244620 A1 JP 2003519123 T WO 0147880 A1	16-01-2003 09-07-2001 05-07-2001 06-08-2003 02-10-2002 17-06-2003 05-07-2001
US 5885834 A	23-03-1999	NONE	